Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6507788 | 0.87 | ALDH1A1 (0.39) | ALDH1A1MEN1LMNAGAAMAPT | |
| SCHEMBL6426277 | 0.81 | ALDH1A1 (0.43) | L3MBTL1ALDH1A1MEN1LMNAGAA | |
| SCHEMBL6427696 | 0.79 | DPP8 (0.34) | ALDH1A1GAA | |
| SCHEMBL6427323 | 0.79 | DPP4 (0.40) | L3MBTL1ALOX12ALDH1A1MEN1LMNA | |
| SCHEMBL6387641 | 0.79 | XIAP (0.36) | CNR2MEN1KMT2A | |
| SCHEMBL14344793 | 0.78 | TSHR (0.42) | L3MBTL1ALDH1A1CYP2C19MEN1KMT2A | |
| SCHEMBL6504880 | 0.78 | TSHR (0.42) | L3MBTL1ALDH1A1CYP2C19MEN1KMT2A | |
| SCHEMBL6503292 | 0.74 | ALDH1A1 (0.35) | L3MBTL1ALDH1A1LMNAGAAMAPT | |
| SCHEMBL6427407 | 0.74 | ALDH1A1 (0.32) | ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL6427367 | 0.73 | MAPT (0.37) | ALDH1A1LMNAGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
| WO-2005075471-A2 | THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | BIOVITRUM AB (SE) | 2005-08-18 | — | — | WO | claimed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | L3MBTL1 4470/4885CNR2 1096/4885DRD2 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.